---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-120257"
form_type: "8-K"
ticker: "IDYA"
cik: "0001676725"
company_name: "IDEAYA Biosciences, Inc."
filed_at: "2024-11-04T23:59:59+00:00"
generated_at: "2026-05-30T06:09:03.023244+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# IDEAYA reports Q3 net loss of $51.8M; cash $1.2B; progress in darovasertib and IDE397 trials

## Summary
- Net loss of $51.8M for Q3 2024; R&D expenses $57.2M; G&A $9.7M.
- Cash, equivalents and marketable securities of $1.2B as of Sep 30, 2024, up from $952.7M due to $283.8M follow-on net proceeds.
- Darovasertib + crizotinib 1L UM registration trial enrollment exceeded 150 patients; successful FDA Type C meeting for neoadjuvant Ph3 targeting H1 2025 initiation.
- IDE397 Phase 1 expansion at ENA 2024 showed 40% confirmed ORR in MTAP-deletion UC, 38% in squamous NSCLC, and 22% in adeno NSCLC.
- IND clearance for IDE275 (Werner helicase) earned $7M milestone from GSK; targeting 3 DC nominations in Q4 2024.

## SEC filing metadata
- accession: 0000950170-24-120257
- form_type: 8-K
- ticker: IDYA
- cik: 0001676725
- company_name: IDEAYA Biosciences, Inc.
- filed_at: 2024-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1676725/000095017024120257/0000950170-24-120257-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1676725/000095017024120257/idya-20241104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-120257
- JSON: https://secwatch.observer/filing/0000950170-24-120257.json
- Plain text: https://secwatch.observer/filing/0000950170-24-120257.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.